{"id":"NCT04193176","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)","officialTitle":"A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-10","primaryCompletion":"2022-08-18","completion":"2022-09-02","firstPosted":"2019-12-10","resultsPosted":"2023-09-22","lastUpdate":"2024-11-05"},"enrollment":376,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Cough"],"interventions":[{"type":"DRUG","name":"Gefapixant","otherNames":["MK-7264"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Gefapixant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in reducing the frequency of cough-induced SUI episodes over 12 weeks.","primaryOutcome":{"measure":"Percent Change From Baseline in Average Daily Cough-induced Stress Urinary Incontinence (SUI) Episodes at Week 12","timeFrame":"Baseline and week 12","effectByArm":[{"arm":"Placebo","deltaMin":-41.09,"sd":null},{"arm":"Gefapixant","deltaMin":-52.78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":90,"countries":["United States","Argentina","Colombia","Germany","Guatemala","Israel","Peru","Russia","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["39222649"],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":190},"commonTop":["Dysgeusia","Ageusia","Headache","Hypogeusia","Nausea"]}}